Cargando…

The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma

Metastatic melanoma is near-to-invariably a fatal disease. As novel therapeutic strategies against metastatic melanoma are urgently needed, we have tested a combinatorial regimen consisting of conventional chemotherapy coupled to bevacizumab, a monoclonal antibody that inhibit angiogenesis, demonstr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mansfield, Aaron S., Nevala, Wendy K., Lieser, Elizabeth Ann T., Leontovich, Alexey A., Markovic, Svetomir N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667915/ https://www.ncbi.nlm.nih.gov/pubmed/23762809 http://dx.doi.org/10.4161/onci.24436

Ejemplares similares

Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma
por: Grotz, Travis E, et al.
Publicado: (2015)

Cancer immune control dynamics: a clinical data driven model of systemic immunity in patients with metastatic melanoma
por: Frisch, Harold P., et al.
Publicado: (2021)

Understanding heterogeneous tumor microenvironment in metastatic melanoma
por: Yan, Yiyi, et al.
Publicado: (2019)

Expansion of CD16-Negative Natural Killer Cells in the Peripheral Blood of Patients with Metastatic Melanoma
por: Holtan, Shernan G., et al.
Publicado: (2011)

Identification of a peptide-peptide binding motif in the coating of nab-paclitaxel nanoparticles with clinical antibodies: bevacizumab, rituximab, and trastuzumab
por: Butterfield, John T., et al.
Publicado: (2017)

A prospective evaluation of the role of Vascular Endothelial Growth Factor (VEGF) and the immune system in stage III/IV melanoma
por: Agostino, Nicole Marie, et al.
Publicado: (2015)

Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: a pilot study
por: Markovic, Svetomir N., et al.
Publicado: (2018)

Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer Therapeutics
por: Enninga, Elizabeth Ann L., et al.
Publicado: (2015)

Quantitative spatial evaluation of tumor-immune interactions in the immunotherapy setting of metastatic melanoma lymph nodes
por: Maus, Rachel L. G., et al.
Publicado: (2022)

Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992–2011
por: Enninga, Elizabeth Ann L., et al.
Publicado: (2017)

Fetal Sex-Based Differences in Maternal Hormones, Angiogenic Factors, and Immune Mediators During Pregnancy and the Postpartum Period
por: Enninga, Elizabeth Ann L, et al.
Publicado: (2015)

Resolving the Heterogeneous Tumor-Centric Cellular Neighborhood through Multiplexed, Spatial Paracrine Interactions in the Setting of Immune Checkpoint Blockade
por: Maus, Rachel L.G., et al.
Publicado: (2022)

Therapy for metastatic melanoma: the past, present, and future
por: Finn, Laura, et al.
Publicado: (2012)

Identification of novel, immune-mediating extracellular vesicles in human lymphatic effluent draining primary cutaneous melanoma
por: Maus, Rachel L.G., et al.
Publicado: (2019)

Development and External Validation of a Prognostic Nomogram for Metastatic Uveal Melanoma
por: Valpione, Sara, et al.
Publicado: (2015)

Endogenous Heat‐Shock Protein Induction with or Without Radiofrequency Ablation or Cryoablation in Patients with Stage IV Melanoma
por: Domingo‐Musibay, Evidio, et al.
Publicado: (2017)

Human Melanoma-Derived Extracellular Vesicles Regulate Dendritic Cell Maturation
por: Maus, Rachel L. G., et al.
Publicado: (2017)

Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20(+) B-cell lymphoma
por: Nevala, Wendy K., et al.
Publicado: (2017)

Growth Modeling of the Maternal Cytokine Milieu throughout Normal Pregnancy: Macrophage-Derived Chemokine Decreases as Inflammation/Counterregulation Increases
por: Holtan, Shernan G., et al.
Publicado: (2015)

Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era
por: Youland, Ryan S., et al.
Publicado: (2017)

Bim and PD-1 identify effector CD8 T cells responsive to anti-PD-1 therapy in metastatic melanoma patients
por: Dronca, Roxana, et al.
Publicado: (2015)

Dominant effects of Δ40p53 on p53 function and melanoma cell fate
por: Takahashi, Rie, et al.
Publicado: (2013)

18F-FDG PET response and clinical outcomes after stereotactic body radiation therapy for metastatic melanoma
por: Youland, Ryan S., et al.
Publicado: (2017)

Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy
por: Davidson, Tara M, et al.
Publicado: (2022)

Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy
por: Schuster, Cornelia, et al.
Publicado: (2018)

Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG‐N0377, Alliance)
por: Vera Aguilera, Jesus, et al.
Publicado: (2018)

Modeling Efficacy of Bevacizumab Treatment for Metastatic Colon Cancer
por: Islam, Rezwan, et al.
Publicado: (2013)

Contraction of T cell richness in lung cancer brain metastases
por: Mansfield, Aaron S., et al.
Publicado: (2018)

β2‐adrenergic receptor expression in patients receiving bevacizumab therapy for metastatic melanoma
por: Schuster, Cornelia, et al.
Publicado: (2023)

Phytochemicals as Immunomodulatory Agents in Melanoma
por: Tabolacci, Claudio, et al.
Publicado: (2023)

Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients
por: Vera Aguilera, Jesus, et al.
Publicado: (2020)

DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2018)

Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab
por: Epistolio, Samantha, et al.
Publicado: (2021)

Immunomodulatory Drugs in Melanoma Brain Metastases
por: Fernandes, Gil Nuno Castro
Publicado: (2019)

Bevacizumab treatment of meningeal melanoma metastases
por: Simonsen, Trude G., et al.
Publicado: (2020)

Immune checkpoint molecules soluble program death ligand 1 and galectin‐9 are increased in pregnancy
por: Enninga, Elizabeth Ann L., et al.
Publicado: (2017)

Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension
por: Schuster, Cornelia, et al.
Publicado: (2012)

Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma
por: Piperno-Neumann, Sophie, et al.
Publicado: (2016)

The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer
por: Yin, Chenxi, et al.
Publicado: (2016)

Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer
por: Passardi, Alessandro, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5m4pp3cddbld244ug82n7fdjns